Chimerix
Chimerix, Inc. was a biopharmaceutical company headquartered in Durham, North Carolina, focused on developing medicines for serious and life-threatening diseases. It is best known for brincidofovir (TEMBEXA), an antiviral approved by the U.S. FDA in 2021 as a smallpox medical countermeasure, and for dordaviprone (ONC201), an investigational small-molecule therapy for H3 K27M-mutant diffuse glioma, a form of brain cancer. Chimerix was a publicly traded company (NASDAQ: CMRX) and was acquired by Jazz Pharmaceuticals in 2025, primarily for dordaviprone; the chimerix.com domain now redirects to jazzpharma.com. As a clinical-stage pharmaceutical company, Chimerix does not operate a public developer program or API surface — this profile tracks it as a company entity within the API Evangelist network.
Chimerix is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Oncology, and Antivirals.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API